<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596791</url>
  </required_header>
  <id_info>
    <org_study_id>Santen-77552</org_study_id>
    <secondary_id>EudraCT number 2007-004872-37</secondary_id>
    <nct_id>NCT00596791</nct_id>
  </id_info>
  <brief_title>Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops</brief_title>
  <official_title>Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if changes in ocular signs and symptoms occur in
      patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005%
      (Xalatan) to preservative free Tafluprost eye drops.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from screening in ocular symptoms and signs</measure>
    <time_frame>at week 6 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Quality of life parameters.</measure>
    <time_frame>From Screening (visit 1) to visits at week 2, 6 and 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>1 arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-lable study with one arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafluprost</intervention_name>
    <description>prostaglandine analoque</description>
    <arm_group_label>1 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the
             patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable
             patients must have ocular surface related symptoms and/or signs with their prior
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu Uusitalo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Finn-Medi Research, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Finn-Medi Research Oy</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Auli Ropo, Study Director</name_title>
    <organization>Santen Oy</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

